Aurobindo Pharma Limited — JV/Acquisition, 23-12-2025: Acquisition

Aurobindo Pharma's subsidiary, Helix Healthcare, is increasing its stake in Chinese JV Luoxin Aurovitas Pharma from 30% to 50%. This acquisition of an additional 20% is valued at $5.125 million (approx. ₹42.5 Cr) cash. The strategic move aims to expand manufacturing capacity for inhalation products by adding two high-speed lines, catering to rising market demand in China. Luoxin Aurovitas reported a turnover of $2.34 million (approx. ₹19.4 Cr) in FY25. Aurobindo also holds an option to fully acquire the remaining 50% for $18.86 million (approx. ₹156.5 Cr) by December 2029.